Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Anticancer immunotoxin available for licensing from NIH

Jan. 4, 1999

Promising phase III trial results presented for Coulter's lead cancer therapy

Dec. 29, 1998

Merck obtains option to expand MDX-447 collaboration with Medarex

Dec. 29, 1998

FDA grants fast track designation for OvaRex MAb

Dec. 22, 1998

Cell Genesys and Japan Tobacco enter worldwide collaboration for GVAX cancer vaccine

Dec. 22, 1998

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Dec. 16, 1998

Seattle Genetics initiates a phase I clinical trial of SGN-10

Dec. 16, 1998

AVI BioPharma reports encouraging clinical data from phase II Avicine study

Dec. 15, 1998

MAb-tyrosine kinase inhibitor immunoconjugate induces disease remission in ALL patients

Dec. 14, 1998

Novel GM-CSF-containing fusion toxin shows excellent antileukemia activity in mouse model

Dec. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...